These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 15558815)

  • 1. Society of Urologic Oncology position statement: redefining the management of hormone-refractory prostate carcinoma.
    Chang SS; Benson MC; Campbell SC; Crook J; Dreicer R; Evans CP; Hall MC; Higano C; Kelly WK; Sartor O; Smith JA;
    Cancer; 2005 Jan; 103(1):11-21. PubMed ID: 15558815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of the spectrum of hormone refractory prostate cancer.
    Clarke NW
    Eur Urol; 2006 Sep; 50(3):428-38; discussion 438-9. PubMed ID: 16797118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormone refractory prostate cancer (HRPC): present and future approaches of therapy.
    Di Lorenzo G; De Placido S
    Int J Immunopathol Pharmacol; 2006; 19(1):11-34. PubMed ID: 16569343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer.
    Loblaw DA; Mendelson DS; Talcott JA; Virgo KS; Somerfield MR; Ben-Josef E; Middleton R; Porterfield H; Sharp SA; Smith TJ; Taplin ME; Vogelzang NJ; Wade JL; Bennett CL; Scher HI;
    J Clin Oncol; 2004 Jul; 22(14):2927-41. PubMed ID: 15184404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Current place of chemotherapy in the treatment of hormone-refractory metastatic prostate cancer].
    Breton X; Lechevallier E; Coulange C
    Prog Urol; 2005 Jun; 15(3):398-404. PubMed ID: 16097142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy of advanced prostatic carcinoma.
    Millikan RE
    Semin Oncol; 1999 Apr; 26(2):185-91. PubMed ID: 10597729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current strategies in the treatment of metastatic hormone-refractory prostate cancer.
    Ghosn M; Kattan J; Younes F
    Tunis Med; 2005 Dec; 83 Suppl 12():74. PubMed ID: 16430073
    [No Abstract]   [Full Text] [Related]  

  • 8. Mechanisms of apoptosis resistance and treatment strategies to overcome them in hormone-refractory prostate cancer.
    Uzzo RG; Haas NB; Crispen PL; Kolenko VM
    Cancer; 2008 Apr; 112(8):1660-71. PubMed ID: 18278811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second-line chemotherapy for advanced hormone-refractory prostate cancer.
    Garmey EG; Sartor O; Halabi S; Vogelzang NJ
    Clin Adv Hematol Oncol; 2008 Feb; 6(2):118-22, 127-32. PubMed ID: 18347563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiotherapy combined with hormonal therapy (RT-HT) in prostate cancer patients with low, intermediate, and high risk of biochemical recurrence: perspective and therapeutic gain analysis.
    Milecki P; Kwias Z; Martenka DJ
    Neoplasma; 2007; 54(1):7-15. PubMed ID: 17203887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New standards in the chemotherapy of metastatic hormone-refractory prostate cancer.
    Sava T; Basso U; Porcaro A; Cetto GL
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):53-62. PubMed ID: 15757438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinoma.
    Rozhansky F; Chen MH; Cox MC; Dahut W; Figg WD; D'Amico AV
    Cancer; 2006 Jan; 106(1):63-7. PubMed ID: 16333854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Radiotherapy combined with hormonal therapy as treatment method in patients with prostate cancer: still more questions than answers].
    Milecki P
    Przegl Lek; 2005; 62(12):1455-9. PubMed ID: 16786772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocrine approaches in the therapy of prostate carcinoma.
    d'Ancona FC; Debruyne FM
    Hum Reprod Update; 2005; 11(3):309-17. PubMed ID: 15790600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New drugs in prostate cancer.
    Armstrong AJ; Carducci MA
    Curr Opin Urol; 2006 May; 16(3):138-45. PubMed ID: 16679849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy for hormone-refractory prostate cancer: now it's a question of "when?".
    Ryan CJ; Eisenberger M
    J Clin Oncol; 2005 Nov; 23(32):8242-6. PubMed ID: 16278479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of hormone refractory prostate cancer.
    Lin AM; Small EJ
    Curr Opin Support Palliat Care; 2007 Oct; 1(3):187-91. PubMed ID: 18685361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of hormonal refractory metastatic prostate cancer].
    Sengeløv L; Klarskov OP; Karlsson S
    Ugeskr Laeger; 2007 May; 169(20):1905-7. PubMed ID: 17553368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What is the pathophysiology of a hormone-resistant prostate tumour?
    Tombal B
    Eur J Cancer; 2011 Sep; 47 Suppl 3():S179-88. PubMed ID: 21943973
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.